Cited by 1,257Ovarian function and disordersDiabetes, Cardiovascular Risks, and LipoproteinsGestational Diabetes Research and Management

The DOI matches its Crossref record.

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

Ehrmann, D A, Barnes, R B, Rosenfield, R L, Cavaghan, M K, Imperial, J·1999·Diabetes Care

DOI 10.2337/diacare.22.1.141

Open this paper in CoChat — free account

Abstract

OBJECTIVE: NIDDM occurs commonly among women with polycystic ovary syndrome (PCOS). The prevalence and natural history of its precursor, impaired glucose tolerance (IGT), is less well known. The objective of this study was to characterize the prevalence and incidence of glucose intolerance in a large cohort of women with well-characterized PCOS. RESEARCH DESIGN AND METHODS: A total of 122 women with clinical and hormonal evidence of PCOS were recruited from the Medicine, Endocrinology, Gynecology, and Pediatrics Clinics at the University of Chicago. All women had a standard oral glucose tolerance test (OGTT) with measurement of glucose and insulin levels. A subset of 25 women were subsequently restudied with the aim of characterizing the natural history of glucose tolerance in PCOS. RESULTS: Glucose tolerance was abnormal in 55 (45%) of the 122 women: 43 (35%) had IGT and 12 (10%) had NIDDM at the time of initial study. The women with NIDDM differed from those with normal glucose tolerance in that they had a 2.6-fold higher prevalence of first-degree relatives with NIDDM (83 vs. 31%, P < 0.01 by chi 2) and were significantly more obese (BMI 41.0 +/- 2.4 vs. 33.4 +/- 1.1 kg/m2, P < 0.01). For the entire cohort of 122 women, there was a significant correlation between fasting and 2-h glucose concentrations (r = 0.76, P < 0.0001); among the subset with IGT, the fasting glucose concentration was poorly predictive of the 2-h level (r = 0.25, NS). After a mean follow-up of 2.4 +/- 0.3 years (range 0.5-6.3), 25 women had a second OGTT. The glucose concentration at 2 h during the second glucose tolerance test was significantly higher than the 2-h concentration during the first study (161 +/- 9 vs. 139 +/- 6 mg/dl, P < 0.02). CONCLUSIONS: The prevalence of IGT and NIDDM in women with PCOS is substantially higher than expected when compared with age- and weight-matched populations of women without PCOS. The conversion from IGT to NIDDM is accelerated in PCOS. The fasting glucose concentration does not reliably predict the glucose concentration at 2 h after an oral glucose challenge, particularly among those with IGT, the subgroup at highest risk for subsequent development of NIDDM. We conclude that women with PCOS should periodically have an OGTT and must be closely monitored for deterioration in glucose tolerance.

Integrity signals

Registry

Crossref · 10.2337/diacare.22.1.141

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 301–400 of 1,000

Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome
Diamanti‐Kandarakis, E., Katsikis, I., Piperi, C., Alexandraki, K., & Panidis, D. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02693.x · Cited by 69
Relationship between Polycystic Ovarian Syndrome and Subsequent Gestational Diabetes Mellitus: A Nationwide Population-Based Study
Pan, M.-L., Chen, L.-R., Tsao, H.-M., & Chen, K.-H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140544 · Cited by 70
“Approximately 50% of women with PCOS have co-existing metabolic syndrome [5,6], in whom insulin resistance is a common endocrine disorder and the risk of developing type 2 overt diabetes mellitus (DM) is 5-8-fold over women without PCOS [6,7].”
Background
Is Interleukin‐17 Involved in the Interaction Between Polycystic Ovary Syndrome and Gingival Inflammation?
Özçaka, Ö., Buduneli, N., Ceyhan, B. Ö., Akcalı, A., Hannah, V., Nile, C. J., & Lappin, D. F. (2013) · Journal of Periodontology · doi:10.1902/jop.2013.120483 · Cited by 69
Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo‐controlled study in polycystic ovary syndrome
Glintborg, D., Frystyk, J., Højlund, K., Andersen, K. K., Henriksen, J. E., Hermann, A. P., Hagen, C., Flyvbjerg, A., & Andersen, M. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03015.x · Cited by 69
Prevalence of gestational diabetes mellitus and pregnancy outcomes in Asian women with polycystic ovary syndrome
Weerakiet, S., Srisombut, C., Rojanasakul, A., Panburana, P., Thakkinstian, A., & Herabutya, Y. (2004) · Gynecological Endocrinology · doi:10.1080/09513590400007242 · Cited by 69
Comparison of clinical features and health manifestations in lean vs. obese Indian women with polycystic ovarian syndrome
Singh, T., & Majumdar, A. (2009) · Journal of Human Reproductive Sciences · doi:10.4103/0974-1208.51336 · Cited by 68
MECHANISMS IN ENDOCRINOLOGY: Recent advances in cardiovascular aspects of polycystic ovary syndrome
Sathyapalan, T., & Atkin, S. L. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0755 · Cited by 69
Statins for women with polycystic ovary syndrome not actively trying to conceive
Raval, A. D., Hunter, T., Stuckey, B. G. A., & Hart, R. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008565.pub2 · Cited by 68
Progression of glucose intolerance and cardiometabolic risk factors over a decade in Chinese women with polycystic ovary syndrome: A case-control study
Ng, N. Y. H., Jiang, G., Cheung, L. P., Zhang, Y., Tam, C. H. T., Luk, A. O. Y., Quan, J., Lau, E. S. H., Yau, T., Chan, M. H. M., et al. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002953 · Cited by 70
“The conversion from IGT to T2DM is also accelerated in PCOS [1,7].”
Background
Habitual dietary intake, eating pattern and physical activity of women with polycystic ovary syndrome
Barr, S., Hart, K. H., Reeves, S., Sharp, K., & Jeanes, Y. (2011) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2011.81 · Cited by 65
Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome
Unfer, V., & Porcaro, G. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.925795 · Cited by 68
Polycystic ovary syndrome (PCOS)
Dewailly, D., Hiéronimus, S., Mirakian, P., & Hugues, J. (2010) · Annales d Endocrinologie · doi:10.1016/j.ando.2009.12.003 · Cited by 67
Puberty and its disorders in the female
Rosenfield, R. L., Cooke, D. W., & Radovick, S. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00024-x · Cited by 67
Self-citation
Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced?
Tomlinson, J., Millward, A., Stenhouse, E., & Pinkney, J. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02994.x · Cited by 66
Chronic Inflammation in PCOS: The Potential Benefits of Specialized Pro-Resolving Lipid Mediators (SPMs) in the Improvement of the Resolutive Response
Regidor, P., Mueller, A., Sailer, M., Santos, F. G., Rizo, J. M., & Egea, F. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010384 · Cited by 70
“PCOS is further characterized by an elevated LH/FSH ratio and often associated with obesity and insulin resistance leading to an hyperinsulinemic state in 80% of the obese women and 30–40% of the lean ones [3].”
Background
Body Iron Stores Are Increased in Overweight and Obese Women With Polycystic Ovary Syndrome
Escobar-Morreale, H. F., Luque‐Ramírez, M., Álvarez‐Blasco, F., Botella-Carretero, J. I., Sancho, J., & Millán, J. L. S. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.2042 · Cited by 66
“Given that insulin resistance and an increased risk of type 2 diabetes are frequent in patients with polycystic ovary syndrome (PCOS) (4,5), we hypothesize that body iron stores might be especially increased in these women.”
Cardiometabolic Risk in PCOS: More than a Reproductive Disorder
Torchen, L. C. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0956-2 · Cited by 65
Is There an Interaction Between Polycystic Ovary Syndrome and Gingival Inflammation?
Özçaka, Ö., Ceyhan, B. Ö., Akcalı, A., Bıçakçı, N., Lappin, D. F., & Buduneli, N. (2012) · Journal of Periodontology · doi:10.1902/jop.2012.110588 · Cited by 65
Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome
Glintborg, D., Altinok, M., Mumm, H., Buch, K., Ravn, P., & Andersen, M. (2014) · Human Reproduction · doi:10.1093/humrep/deu133 · Cited by 65
“…6, 2014 study question: Is there an association between prolactin and markers of metabolic risk in polycystic ovary syndrome (PCOS)? summary answer: Low serum prolactin was a metabolic risk marker in PCOS. what is known already: Prolactin is routinely measured to exclude endocrine diseases in PCOS.”
Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers
Patel, S. S., Truong, U. T., King, M., Ferland, A., Moreau, K. L., Dorosz, J. L., Hokanson, J. E., Wang, H., Kinney, G. L., Maahs, D. M., et al. (2017) · Vascular Medicine · doi:10.1177/1358863x16682107 · Cited by 70
Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome?
Loucks, T. L., Talbott, E. O., McHugh-Pemu, K. P., Keelan, M. H., Berga, S. L., & Guzick, D. S. (2000) · Fertility and Sterility · doi:10.1016/s0015-0282(00)00695-6 · Cited by 65
Prevention of diabetes and cardiovascular disease in women with PCOS: Treatment with insulin sensitizers
Sharma, S. T., & Nestler, J. E. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.02.003 · Cited by 64
Transcriptional Profiling with a Pathway-Oriented Analysis Identifies Dysregulated Molecular Phenotypes in the Endometrium of Patients with Polycystic Ovary Syndrome
Kim, J. Y., Song, H., Kim, H., Kang, H. J., Jun, J. H., Hong, S. R., Koong, M. K., & Kim, I. S. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1612 · Cited by 64
Cardiometabolic risk in polycystic ovary syndrome
Studen, K. B., & Pfeifer, M. (2018) · Endocrine Connections · doi:10.1530/ec-18-0129 · Cited by 66
The HMGA2-IMP2 Pathway Promotes Granulosa Cell Proliferation in Polycystic Ovary Syndrome
Li, M., Zhao, H., Zhao, S., Wei, D., Zhao, Y., Huang, T., Muhammad, T., Yan, L., Gao, F., Li, L., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00544 · Cited by 64
Amelioration of insulin resistance in women with PCOS via reduced insulin receptor substrate-1 Ser312 phosphorylation following laparoscopic ovarian electrocautery
Seow, K., Juan, C., Hsu, Y.-P., Hwang, J., Huang, L., & Ho, L. (2007) · Human Reproduction · doi:10.1093/humrep/del466 · Cited by 64
Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI: IGT in adolescent polycystic ovary syndrome
Flannery, C. A., Rackow, B., Cong, X., Duran, E., Selen, D. J., & Burgert, T. S. (2013) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2012.00902.x · Cited by 62
“In particular, impaired glucose tolerance (IGT), the most prevalent (31–35%) glucose abnormality in women with PCOS (4, 5), has not been examined systematically in adolescents.”
Background
Estradiol Binds to Insulin and Insulin Receptor Decreasing Insulin Binding in vitro
Root-Bernstein, R. S., Podufaly, A., & Dillon, P. F. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00118 · Cited by 63
Glucose intolerance states in women with the polycystic ovary syndrome
Pasquali, R., & Gambineri, A. (2013) · Journal of Endocrinological Investigation · doi:10.1007/bf03346757 · Cited by 63
“(collectively including 784 women) found that more than 10% per cent of the women had T2D (26-28) and two uncontrolled studies found very high rates (32% and 15.”
MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome
Glintborg, D., & Andersen, M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0373 · Cited by 66
The Flavanone, Naringenin, Modifies Antioxidant and Steroidogenic Enzyme Activity in a Rat Model of Letrozole-Induced Polycystic Ovary Syndrome
Hong, Y., Yin, Y., Tan, Y., Hong, K., & Zhou, H. (2019) · Medical Science Monitor · doi:10.12659/msm.912341 · Cited by 65
“Previously published studies during the past few decades have shown that PCOS is associated with an increased risk of type 2 diabetes mellitus [4].”
Background
Retracted
Chinese herbal medicine for subfertile women with polycystic ovarian syndrome
Zhou, K., Zhang, J., Xu, L., Wu, T., & Lim, C. E. D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007535.pub3 · Cited by 61
Polycystic ovarian syndrome – prognosis and outcomes
Hart, R. J., & Norman, R. J. (2006) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2006.04.006 · Cited by 63
Relationship between risk factors for infertility in women and lead, cadmium, and arsenic blood levels: a cross-sectional study from Taiwan
Lei, H.-L., Wei, H., Ho, H.-Y., Liao, K., & Chien, L. (2015) · BMC Public Health · doi:10.1186/s12889-015-2564-x · Cited by 65
“Patients with prediagnosed diabetes mellitus, nonclassical adrenal 21-hydroxylase deficiency, hyperprolactinemia, or androgen-secreting tumors were excluded from the current study [25–27].”
Background
Treatment of polycystic ovary syndrome with insulin-lowering agents
Wang, P., Streicher, P., & Glueck, C. J. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.8.1177 · Cited by 63
“The insulin resistance characteristic of PCOS is directly and causally related to gestational diabetes, IGT and ultimately, Type 2 diabetes (Figure 1) [10,49,77-81].”
Background
Biochemistry of infertility
Wasilewski, T., Łukaszewicz-Zając, M., Wasilewska, J., & Mroczko, B. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.05.039 · Cited by 61
Lipid and lipoprotein profile in women with polycystic ovary syndromeThis article is one of a selection of papers published in the special issue Bridging the Gap: Where Progress in Cardiovascular and Neurophysiologic Research Meet.
Μacut, D., Panidis, D., Glišić, B., Spanos, N., Petakov, M. S., Bjekić, J., Stanojlović, O. P., Rousso, D., Kourtis, A., Antić, I. B., et al. (2008) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y08-014 · Cited by 61
Polycystic Ovary Syndrome in the Adolescent
Pfeifer, S. M., & Kives, S. L. (2009) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2008.12.004 · Cited by 60
“5% to 10% had type II diabetes and approximately 30% to 35% had impaired glucose tolerance.(19,20) The incidence of type II diabetes and impaired glucose tolerance in the control population was significantly lower at 0% and 14%, respectively.”
Polycystic Ovary Syndrome: Early Detection in the Adolescent
Chang, R. J., & Coffler, M. S. (2007) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31802f50fc · Cited by 60
“The prevalence of insulin resistance in PCOS has been reported to range between 20% and 40%.(13) That insulin resistance is common in obesity may account, in part, for the rather wide prevalence.”
Background
Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome
Checa, M. Á., Requena, A., Salvador, C., Tur, R., Callejo, J., Espinós, J. J., Fábregues, F., Herrero, J. C., & (Reproductive Endocrinology Interest Group of the Spanish Society of Fertility) (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi015 · Cited by 60
“5–10%) (Ehrmann et al., 1999), with 5–10-fold increased rate of conversion of impaired glucose tolerance to non-insulin”
BackgroundInfluential
Dietary management of women with polycystic ovary syndrome in the United Kingdom: The role of dietitians
Jeanes, Y. M., Barr, S., Smith, K., & Hart, K. H. (2009) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2009.00988.x · Cited by 59
Phosphoprotein enriched in astrocytes (PEA)-15: A potential therapeutic target in multiple disease states
Greig, F. H., & Nixon, G. F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.006 · Cited by 59
“The altered steroid milieu of PCOS is associated with abnormalities in glucose homeostasis and insulin secretion with about 30 to 40% of women diagnosed with glucose intolerance and 10% with type 2 diabetes (Ehrmann et al., 1999; Savastano et al., 2007).”
Background
Follicular Fluid: A Powerful Tool for the Understanding and Diagnosis of Polycystic Ovary Syndrome
Brinca, A. T., Ramalhinho, A. C., Sousa, Â., Oliani, A. H., Breitenfeld, L., Passarinha, L. A., & Gallardo, E. (2022) · Biomedicines · doi:10.3390/biomedicines10061254 · Cited by 65
Insulin resistance in patients with polycystic ovary syndrome
Schröder, A. K., Tauchert, S., Ortmann, O., Diedrich, K., & Weiss, J. M. (2004) · Annals of Medicine · doi:10.1080/07853890410035296 · Cited by 59
Prevalence of the metabolic syndrome in Asian women with polycystic ovary syndrome: Using the International Diabetes Federation criteria
Weerakiet, S., Bunnag, P., Phakdeekitcharoen, B., Wansumrith, S., Chanprasertyothin, S., Jultanmas, R., & Thakkinstian, A. (2007) · Gynecological Endocrinology · doi:10.1080/09513590701214158 · Cited by 59
Polycystic ovarian syndrome (PCOS) and insulin resistance
Park, K. H., Kim, J. Y., Ahn, C. W., Song, Y. D., Lim, S.-K., & Lee, H. C. (2001) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(01)00442-8 · Cited by 59
Prediction models for insulin resistance in the polycystic ovary syndrome
Gennarelli, G. (2000) · Human Reproduction · doi:10.1093/humrep/15.10.2098 · Cited by 59
Type 2 diabetes mellitus in adolescents
Callahan, S. T., & Mansfield, M. J. (2000) · Current Opinion in Pediatrics · doi:10.1097/00008480-200008000-00004 · Cited by 59
Omentin and chemerin and their association with obesity in women with polycystic ovary syndrome
Güzel, E. Ç., Celik, C., Abalı, R., Küçükyalçın, V., Celik, E., GÜZEL, M., & Yılmaz, M. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2014.888412 · Cited by 58
Characteristics of Adolescents Presenting to a Multidisciplinary Clinic for Polycystic Ovarian Syndrome
Bekx, M. T., Connor, E. L., & Allen, D. B. (2009) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2009.04.004 · Cited by 58
“2%).(5,6) The incidence of glucose metabolic derangement in the young adult and adolescent population with PCOS is unknown.”
Background
rs4889 polymorphism in KISS1 gene, its effect on polycystic ovary syndrome development and anthropometric and hormonal parameters in Saudi women
Albalawi, F. S., Daghestani, M. H., Daghestani, M. H., Eldali, A., & Warsy, A. S. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0452-2 · Cited by 58
“[14], type 2 diabetes mellitus (DM), cardio-vascular disease and infertility [15, 16].”
Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
Kalra, S., Das, A. K., Sahay, R. K., Baruah, M. P., TIWASKAR, M. H., Das, S., Chatterjee, S., Saboo, B., Bantwal, G., Bhattacharya, S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0669-4 · Cited by 64
Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women?
Talbott, E. O. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1452 · Cited by 58
The Investigation of Insulin Resistance in Patients with Idiopathic Hirsutism
Ünlühızarcı, K., Karababa, Y., Bayram, F., & Keleştimur, F. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031626 · Cited by 57
Diagnostic Criteria for Polycystic Ovarian Syndrome
Broekmans, F. J., & Fauser, B. C. J. M. (2006) · Endocrine · doi:10.1385/endo:30:1:3 · Cited by 56
Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria
Alebić, M. Š., Bulum, T., Stojanović, N., & Duvnjak, L. S. (2014) · Endocrine · doi:10.1007/s12020-014-0182-5 · Cited by 56
“DISCUSSION In this study, PCOS women had higher HOMA-IR than non-PCOS women (controls) even after controlling for BMI and age which is indicative of decreased insulin sensitivity in PCOS and, thus, a higher risk for developing IR-associated metabolic disorders such as impaired glucose tolerance, type 2 diabetes, the m…”
Background
The ESHRE/ASRM consensus on polycystic ovary syndrome (PCOS) – an extended critical analysis
Geisthövel, F., & Rabe, T. (2007) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60902-9 · Cited by 56
Serum adiponectin and lipid concentrations in pregnant women with polycystic ovary syndrome
Sir‐Petermann, T., Echiburú, B., Maliqueo, M. A., Crisosto, N., Sanchez, F., Hitschfeld, C., Cárcamo, M., Amigo, P., & Pérez‐Bravo, F. (2007) · Human Reproduction · doi:10.1093/humrep/dem090 · Cited by 55
“In addition, women with PCOS may also have other metabolic abnormalities such as insulin resistance (Holte, 1996; Dunaif, 1997), glucose intolerance, type 2 diabetes (Ehrmann et al., 1999; Legro et al., 1999; Gambineri et al., 2002) and an increased prevalence of lipid-related abnormalities (Wild, 1997; Legro et al.”
Background
Polycystic Ovarian Syndrome (PCOS): A Significant Contributor to The Overall Burden of Type 2 Diabetes in Women
Talbott, E. O., Zborowski, J. V., Rager, J. R., Kip, K. E., Xu, X., & Orchard, T. J. (2007) · Journal of Women s Health · doi:10.1089/jwh.2006.0098 · Cited by 56
Plasma visfatin levels in normal weight women with polycystic ovary syndrome
Panidis, D., Farmakiotis, D., Rousso, D., Katsikis, I., Delkos, D., Piouka, A., Gerou, S., & Diamanti‐Kandarakis, E. (2008) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2007.05.014 · Cited by 55
“PCOS is frequently associated with central obesity, IGT (up to 35%), and T2DM (up to 10%) [32].”
Background
Sex differences in the effects of androgens acting in the central nervous system on metabolism
Morford, J. J., & Mauvais‐Jarvis, F. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.4/fmauvais · Cited by 53
Association of +45G15G(T/G) and +276(G/T) polymorphisms in the ADIPOQ gene with polycystic ovary syndrome among Han Chinese women
Zhang, N., Shi, Y., Hao, C., Gu, H. F., Li, Y., Zhao, Y., Wang, L., & Chen, Z. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0576 · Cited by 54
Insulin resistance in polycystic ovary syndrome is associated with defective regulation of ERK1/2 by insulin in skeletal muscle in vivo
Rajkhowa, M., Brett, S., Cuthbertson, D. J., Lipina, C., Ruiz‐Alcaraz, A. J., Thomas, G. E., Logie, L., Petrie, J. R., & Sutherland, C. D. (2008) · Biochemical Journal · doi:10.1042/bj20082176 · Cited by 56
The role of the endogenous opioid system in polycystic ovary syndrome
Eyvazzadeh, A. D., Pennington, K. P., Pop‐Busui, R., Sowers, M., Zubieta, J., & Smith, Y. R. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.05.012 · Cited by 54
Obesity-Related Lipid Profile and Altered Insulin Incretion in Adolescents With Polycystic Ovary Syndrome
Fulghesu, A. M., Magnini, R., Portoghese, E., Angioni, S. L., Minerba, L., & Melis, G. B. (2010) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2009.10.008 · Cited by 54
Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study
Florakis, D., Diamanti‐Kandarakis, E., Katsikis, I., Nassis, G. P., Karkanaki, A., Georgopoulos, N. A., & Panidis, D. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803777 · Cited by 53
Diabetes and impaired glucose tolerance in patients with polycystic ovary syndrome--a long term follow-up
Hudecova, M., Holte, J., Olovsson, M., Larsson, A. O., Berne, C., & Poromaa, I. S. (2011) · Human Reproduction · doi:10.1093/humrep/der065 · Cited by 53
“Corresponding figures for control subjects were one woman with type 2 diabetes (1.1%), two women with IGT (2.3”
BackgroundResultInfluential
Diabetes Prevalence and Risk Factors in Polycystic Ovary Syndrome
Legro, R. S. (2001) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70188-1 · Cited by 53
PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN WOMEN WITH POLYCYSTIC OVARY SYNDROME AND ITS CORRELATION WITH METABOLIC SYNDROME
Romanowski, M. D., Parolin, M. B., de Freitas, A. C. T., Piazza, M. J., BASSO, J., & Urbanetz, A. A. (2015) · Arquivos de Gastroenterologia · doi:10.1590/s0004-28032015000200008 · Cited by 53
“; Inclusion criteria Women aged ≥18 years old with con!rmed diagnosis of PCOS based on criteria established by the Androgen Excess Society Guidelines((12)), not using hormonal contraception for at least 3 months, were included.”
BackgroundMethodInfluential
Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin
Cibula, D. (2002) · Human Reproduction · doi:10.1093/humrep/17.1.76 · Cited by 53
Effect of high-protein or normal-protein diet on weight loss, body composition, hormone, and metabolic profile in southern Brazilian women with polycystic ovary syndrome: A randomized study
Toscani, M. K., Mario, F. M., Radavelli-Bagatini, S., Wiltgen, D., Cristina Matos, M., & Spritzer, P. M. (2011) · Gynecological Endocrinology · doi:10.3109/09513590.2011.564686 · Cited by 52
“Polycystic ovary syndrome (PCOS), an endocrine disorder affecting 7–10% of women of reproductive age, is often associated with obesity, insulin resistance (IR) [1,2], and metabolic syndrome [1,3].”
Background
The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome
Lee, H., Oh, J. Y., Sung, Y., Chung, H., & Cho, W. Y. (2009) · Endocrine · doi:10.1007/s12020-009-9226-7 · Cited by 55
“Thus, our data from Korean women with PCOS agree with that of Mediterranean [18] and Chinese women with PCOS [6], which contrast with observations from American women with PCOS [3, 5]. Although some differences may exist in the selection criteria among these various studies [3, 5 , 6, 18], our present data provide gro…”
BackgroundResultInfluential
Metabolic abnormalities in adolescents with polycystic ovary syndrome in south china
Huang, J., Ni, R., Chen, X., Huang, L., Mo, Y., & Yang, D. (2010) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-8-142 · Cited by 52
“The prevalence of IGT was 31-35% in adults, while DM was 7.5-10% [23, 24 ].”
BackgroundInfluential
Low sex hormone-binding globulin as a predictive marker for insulin resistance in women with hyperandrogenic syndrome
Kajaia, N., Binder, H., Dittrich, R., Oppelt, P. G., Flor, B. D. A., Cupisti, S., Beckmann, M. W., & Mueller, A. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0203 · Cited by 52
“Diagnosing IR in women with hyperandrogenic syndrome or androgen excess may help identify endocrine and metabolic risk factors and reveal individuals suitable for targeted treatment with insulin sensitizers, to improve therapeutic approaches and prevent complications later in life (11, 12).”
The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology
Karkanaki, A., Vosnakis, C., & Panidis, D. (2011) · HORMONES · doi:10.14310/horm.2002.1299 · Cited by 52
“The incidence of diabetes mellitus type 2 is 10-fold higher in women with PCOS compared to healthy women in the USA.(47,48) Furthermore, 30-50% of women with PCOS develop glucose intolerance or diabetes mellitus type 2 after the age of 30.”
BackgroundInfluential
The adipose cell lineage is not intrinsically insulin resistant in polycystic ovary syndrome
Corbould, A. M., & Dunaif, A. E. (2007) · Metabolism · doi:10.1016/j.metabol.2006.12.021 · Cited by 52
“It is characterized by hyperandrogenism, disordered gonadotropin secretion, skeletal muscle insulin resistance, and an increased risk of type 2 diabetes mellitus (DM) [1-4].”
Background
Use of metformin in the treatment of polycystic ovary syndrome
Genazzani, A. D., Ricchieri, F., & Lanzoni, C. (2010) · Women's Health · doi:10.2217/whe.10.43 · Cited by 51
“It is important to remember that several studies, although not all [59], reported that insulin modulates LH secretion from pituitary cells in vitro [53] and in vivo (Figure 3), and that the reduction of hyperinsulinemia induces the significant decrease of LH plasma levels [51,60,61], although it is not clear whether d…”
Background
Increased plasma metastin levels in adolescent women with polycystic ovary syndrome
Chen, X., Mo, Y., Li, L., Chen, Y., Li, Y., & Yang, D. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2009.11.018 · Cited by 60
“PCOS is characterized by hyperandrogenism and chronic anovulation, and its morbidity may include hyperinsulinemia, insulin resistance, early onset of type 2 diabetes mellitus (DM), dyslipidemia, cardiovascular disease and infertility [1–5].”
Background
Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome.
Kurdoğlu, Z., Özkol, H., Tülüce, Y., & Koyuncu, İ. (2012) · PubMed · doi:10.3275/7682 · Cited by 51
Interplay Between Insulin Resistance and Estrogen Deficiency as co- Activators in Carcinogenesis
Suba, Z. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9466-8 · Cited by 55
Hemoglobin A1c as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndrome
Magnussen, L. V., Mumm, H., Andersen, M., & Glintborg, D. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.08.035 · Cited by 51
Polycystic Ovary Syndrome: A Common Endocrine Disorder and Risk Factor for Vascular Disease
McGowan, M. P. (2011) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-011-0130-0 · Cited by 59
“In the United States, about 60% of women with PCOS are obese and insulin resistant and a full 40% will develop diabetes by the age of 50 years [6, 7 ]. Dyslipidemia is likewise highly prevalent and characterized by lower highdensity lipoprotein cholesterol (HDL-C), higher triglycerides, and higher low-density lipoprot…”
Background
Diet-induced obesity exacerbates metabolic and behavioral effects of polycystic ovary syndrome in a rodent model
Ressler, I. B., Grayson, B. E., Ulrich‐Lai, Y. M., & Seeley, R. J. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00182.2014 · Cited by 51
31. Polycystic ovary syndrome and the metabolic syndrome
Hunter, T., & Hart, R. J. (2014) · Wageningen Academic Publishers eBooks · doi:10.3920/978-90-8686-767-7.031 · Cited by 51
Polycystic Ovary Syndrome in Adolescents
Mastorakos, G. P., Lambrinoudaki, I. V., & Creatsas, G. K. (2006) · Pediatric Drugs · doi:10.2165/00148581-200608050-00004 · Cited by 51
Polymorphism T → C (−34 base pairs) of gene CYP17 promoter in women with polycystic ovary syndrome is associated with increased body weight and insulin resistance: a preliminary study
Echiburú, B., Pérez‐Bravo, F., Maliqueo, M. A., Sánchez, F., Crisosto, N., & Sir‐Petermann, T. (2008) · Metabolism · doi:10.1016/j.metabol.2008.08.002 · Cited by 51
“offers the opportunity to detect metabolic abnormalities earlier in these women [7,12].”
Background
Polycystic Ovarian Syndrome and the Metabolic Syndrome
Sartor, B. M., & Dickey, R. P. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200512000-00012 · Cited by 50
Retinol-binding protein 4 levels are elevated in polycystic ovary syndrome women with obesity and impaired glucose metabolism
Hahn, S., Backhaus, M., Broecker‐Preuss, M., Tan, S., Dietz, T., Kimmig, R., Schmidt, M., Mann, K., & Janssen, O. E. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0143 · Cited by 51
Evidence for pancreatic β-cell dysfunction in brothers of women with polycystic ovary syndrome
Sam, S., Sung, Y., Legro, R. S., & Dunaif, A. E. (2007) · Metabolism · doi:10.1016/j.metabol.2007.08.010 · Cited by 48
The Usefulness of Homeostatic Measurement Assessment-Insulin Resistance (HOMA-IR) for Detection of Glucose Intolerance in Thai Women of Reproductive Age with Polycystic Ovary Syndrome
Wongwananuruk, T., Rattanachaiyanont, M., Leerasiri, P., Indhavivadhana, S., Techatraisak, K., Angsuwathana, S., Tanmahasamut, P., & Dangrat, C. (2012) · International Journal of Endocrinology · doi:10.1155/2012/571035 · Cited by 53
Prevalence and predictors of metabolic abnormalities in Chinese women with PCOS: a cross- sectional study
Li, R., Yu, G., Yang, D., Li, S., Lu, S., Wu, X., Wei, Z., Song, X., Wang, X., Fu, S., et al. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-76 · Cited by 50
“Also, previous studies indicated that 30–40 percent women with PCOS have impaired glucose tolerance, and as many as 10 percent have type 2 diabetes by their fourth decade [17,18].”
Background
Phenotype and Tissue Expression as a Function of Genetic Risk in Polycystic Ovary Syndrome
Pau, C. T., Mosbruger, T., Saxena, R., & Welt, C. K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0168870 · Cited by 51
Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis
Yılmaz, B., Vellanki, P., Ata, B., & Yıldız, B. O. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.04.024 · Cited by 53
Cardiometabolic aspects of polycystic ovarian syndrome.
Cho, L. W., Randeva, H. S., & Atkin, S. L. (2007) · PubMed Central · Cited by 50
Prediction of Insulin Sensitivity in Nonobese Women with Polycystic Ovary Syndrome
Cibula, D., Škrha, J., Hill, M., Fanta, M., Haaková, L., Vrbíková, J., & Zivny, J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020586 · Cited by 50
Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: A retrospective analysis
Sharma, S. T., Wickham, E. P., & Nestler, J. E. (2007) · Endocrine Practice · doi:10.4158/ep.13.4.373 · Cited by 49
Metformin Improves Glucose Effectiveness, Not Insulin Sensitivity: Predicting Treatment Response in Women With Polycystic Ovary Syndrome in an Open-Label, Interventional Study
Pau, C. T., Keefe, C. C., Duran, J. M., & Welt, C. K. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4021 · Cited by 50
The relationship between polycystic ovary syndrome, glucose tolerance status and serum preptin level
Bu, Z., Kuok, K., Meng, J., Wang, R., Xu, B., & Zhang, H. (2012) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-10-10 · Cited by 49
“0%, respectively [8,9].”
The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome
Charitidou, C., Farmakiotis, D., Zournatzi, V., Pidonia, I., Pegiou, T., Karamanis, N., Hatzistilianou, M. N., Katsikis, I., & Panidis, D. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.03.002 · Cited by 49
Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?
Moll, E., Korevaar, J. C., Bossuyt, P. M., & van der Veen, F. (2008) · Human Reproduction · doi:10.1093/humrep/den182 · Cited by 48
“Subgroup analysis was performed on age, BMI, WHR, testosterone, 2 h glucose and HOMA (homeostatic model assessment for assessing insulin sensitivity) as a measure of IR (Ehrmann et al., 1999; Legro et al., 1999, 2004; NCEP Expert Panel, 2001; Fauser, 2004; Samaras et al., 2006).”
BackgroundMethod

Authors: Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J.
Affiliations: University of Chicago (US)
ORCID: Rosenfield, R L
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 1999-01-01
Volume: 22
Issue: 1
Pages: 141-146
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/diacare.22.1.141
OpenAlex: W2007816906
Cited by: 1,257
References: 0
Citations by year: 2026: 10 · 2025: 13 · 2024: 22 · 2023: 18 · 2022: 39 · 2021: 45 · 2020: 32 · 2019: 39 · 2018: 40 · 2017: 45 · 2016: 37 · 2015: 63 · 2014: 63 · 2013: 55 · 2012: 75
FWCI: 31.87
Type: journal article
Language: en
Open access: closed
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5k08dk002315-02)
National Institute of Diabetes and Digestive and Kidney Diseases (DK-31842, DK 20595, DK-02315)
Topics: Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
Keywords: polycystic ovary syndrome, impaired glucose tolerance, type 2 diabetes, prevalence, incidence, natural history (disease), oral glucose tolerance test, fasting blood glucose, obesity, family history of diabetes, women's health
MeSH terms: Adult, Analysis of Variance, Blood Glucose, Chicago, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glucose Tolerance Test, Humans, Insulin, Polycystic Ovary Syndrome, Regression Analysis, Testosterone, Prevalence, Glucose Intolerance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks